Literature DB >> 8238212

Results of transantral orbital decompression in 428 patients with severe Graves' ophthalmopathy.

J A Garrity1, V Fatourechi, E J Bergstralh, G B Bartley, C W Beatty, L W DeSanto, C A Gorman.   

Abstract

We reviewed records from 428 consecutive patients with severe Graves' ophthalmopathy to determine early and late results after transantral orbital decompression. Optic neuropathy was present in 217 (50.7%) patients. Post-operatively, 402 (89%) of 453 eyes with preoperative visual acuity worse than 20/20 improved or remained the same. Visual field scotomas improved or resolved in 245 (91%) of 269 eyes tested pre- and postoperatively. Preoperative papilledema resolved or improved in 99 (94%) of 105 eyes, and preoperative exposure keratitis improved or resolved in 178 (92%) of 195 eyes. Average proptosis reduction was 4.7 mm. Postoperatively, new diplopia developed in 74 (64%) of 116 patients who had no diplopia before orbital decompression, although 300 patients ultimately had strabismus surgery. At late follow-up (N = 293 patients), 226 (77%) had single vision and 44 (15%) had correction with prism. Complications included sinusitis (18 patients), lower eyelid entropion (38 patients), numb lip (23 patients), cerebrospinal fluid leaks (15 patients), and one frontal lobe hematoma (one patient). The average duration of follow-up was 8.7 years. Transantral orbital decompression effectively reduces proptosis and usually corrects optic neuropathy. In other circumstances, the benefits achieved and the side effects incurred must be carefully balanced for each patient before transantral orbital decompression is considered.

Entities:  

Mesh:

Year:  1993        PMID: 8238212     DOI: 10.1016/s0002-9394(14)73194-0

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  33 in total

1.  Coronal approach for rehabilitative orbital decompression in Graves' ophthalmopathy.

Authors:  R Kalmann; M P Mourits; J P van der Pol; L Koornneef
Journal:  Br J Ophthalmol       Date:  1997-01       Impact factor: 4.638

Review 2.  [Endocrine orbit disorders. Pathogenesis, clinical presentation and examination, stage-dependent therapy].

Authors:  A Eckstein; J Esser
Journal:  Ophthalmologe       Date:  2003-10       Impact factor: 1.059

3.  [Surgical therapy in Graves' orbitopathy].

Authors:  J Kaminsky; G J Ridder; A Eckstein; M Metzger; F Beisse
Journal:  Ophthalmologe       Date:  2011-05       Impact factor: 1.059

4.  Effects of bilateral orbital decompression by an endoscopic endonasal approach in dysthyroid orbitopathy.

Authors:  A Neugebauer; K Nishino; P Neugebauer; W Konen; O Michel
Journal:  Br J Ophthalmol       Date:  1996-01       Impact factor: 4.638

5.  Early experience with intravenous immunoglobulin treatment in Wegener's granulomatosis with ocular involvement.

Authors:  M Blum; K Andrassy; D Adler; M Hartmann; H E Völcker
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-09       Impact factor: 3.117

6.  [Graves' ophthalmopathy].

Authors:  A Eckstein; J Esser
Journal:  Internist (Berl)       Date:  2010-05       Impact factor: 0.743

Review 7.  [Graves' ophthalmopathy].

Authors:  A Eckstein; D Dekowski; D Führer-Sakel; U Berchner-Pfannschmidt; J Esser
Journal:  Ophthalmologe       Date:  2016-04       Impact factor: 1.059

8.  Orbital decompression surgery for the treatment of Graves' ophthalmopathy: comparison of different techniques and long-term results.

Authors:  Mehmet Ozgur Cubuk; Onur Konuk; Mehmet Unal
Journal:  Int J Ophthalmol       Date:  2018-08-18       Impact factor: 1.779

9.  Reasons for revision surgery after orbital decompression for Graves' orbitopathy.

Authors:  Stefano Sellari-Franceschini; Luca Muscatello; Veronica Seccia; Riccardo Lenzi; Amelia Santoro; Marco Nardi; Barbara Mazzi; Aldo Pinchera; Claudio Marcocci
Journal:  Clin Ophthalmol       Date:  2008-06

10.  [Update on endocrine orbitopathy].

Authors:  A Eckstein; U Berchner-Pfannschmidt; D Führer; J Esser
Journal:  Ophthalmologe       Date:  2013-11       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.